bio-america-crispr-2018-scientifictracks

17 / 20

Page 46
Notes:
&
24th Biotechnology Congress: Research & Innovations
CRISPR Cas9 Technology and Genetic Engineering
Annual Congress on
October 24-25, 2018 | Boston, USA
Journal of Biotechnology & Biomaterials | ISSN: 2155-952X | Volume: 8
RegenerAge system: Therapeutic effects of combinatorial biologics (mRNA and allogenic MSCs)
with a spinal cord stimulation system on a patient with spinal cord section
Joel I Osorio
RegenerAge, USA
Bioquantine® a mRNA extract from Xenopus laevis frog oocytes (purified from intra- and extra-oocyte liquid phases of
electroporated oocytes), showed potential as a treatment for a wide range of conditions in animal models, including Spinal
Cord Injury (SCI) and Traumatic Brain Injuries (TBI) among others. The current study observed beneficial changes with
Bioquantine® administration in a patient with a severe SCI. Pluripotent stem cells have therapeutic and regenerative potential
in clinical situations CNS disorders. One method of reprogramming somatic cells into pluripotent stem cells is to expose
them to extracts prepared from Xenopus laevis oocytes. Due to ethical reasons and legal restrictions we selected a No Option
patient, deciding to include in our protocol the RestoreSensor® SureScan® to complete it. Based on the electrical stimulation for
rehabilitation and regeneration after spinal cord injury published by Hamid and MacEwan, we designed an improved delivery
method for the in situ application of MSCs and Bioquantine® in combination with the RestoreSensor® SureScan®. To the present
day the patient who suffered a complete section of spinal cord at T12-L1 shows an improvement in sensitivity, strength in
striated muscle and smooth muscle connection, 14 months after the first Bioquantine® and MSCs treatment and 9 months
after the placement of RestoreSensor® at the level of the lesion, showing an evident improvement on his therapy of physical
rehabilitation (legs movement) on crawling forward and backwards and standing on his feet for the first time and showing a
progressively important functionality on both limbs.
Biography
Joel I Osorio is an innovative businessman with a distinct entrepreneurial mindset concentrated adding value on areas of Biotechnology (mRNA), Reprogramming
& Regenerative Medicine for translational use in humans and a variety of clinical applications aimed for both the private and the public health sectors. He is the
Founder, President, and CEO of RegenerAge Clinic and RegenerAge Beauty initiatives for transnational implementations. Vice President and International Clinical
Developer for Bioquark, Inc. Executive Vice President: Chairman of the WAMS Americas Division, member of the WAMS Executive Council (WAMS Executive
Board), a member of the WAMS Education and Training Board (ETB), a member of the WAMS Editorial Board, an Honorary Member of the Academy Faculty
FWAMS, an Honorary Fellow of the Academy and is also a Senior Partner at WAMS, The World Academy of Medical Sciences.
Joel I Osorio, J Biotechnol Biomater 2018, Volume 8
DOI: 10.4172/2155-952X-C4-097